Tuberculosis in transplantation: Diagnosis, prevention, and treatment

Current Infectious Disease Reports

Volumn 14, Issue 6, 2012, Pages 650-657

  Kirsch, Sarah ^a   Sester, Martina ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Adaptive immune response; Diagnosis; ELISA; ELISPOT; Flow cytometry; Guidelines; IGRA; Immunodeficiency; Immunosuppression; Infection; Interferon release assay; Latent infection with M. tuberculosis; Management; Mycobacterium tuberculosis; Posttransplant infection .Chemoprophylaxis .Transplantation; Prevention; Screening; Skin testing; Solid organ transplant recipients; Treatment; TST; Tuberculosis

Indexed keywords

BCG VACCINE; CORTICOSTEROID; CYCLOSPORIN A; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TUBERCULIN; VITAMIN D;

ADAPTIVE IMMUNITY; BCG VACCINATION; CYTOKINE RESPONSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PREDICTIVE VALUE; REVIEW; SHORT COURSE THERAPY; TENDON DISEASE; TOXIC HEPATITIS; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84870537193     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0293-1     Document Type: Review

References (52)

1. WHO: Global Tuberculosis Control report. WHO report 2011. In. Geneva, Switzerland, 2011.
2. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40:581-7.
3. Sester U, Wilkens H, van Bentum K, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J. 2009;34:702-10.
4. Vandermarliere A, Van Audenhove A, Peetermans WE, et al. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis. 2003;5:9-15.
5. Basiri A, Hosseini-Moghaddam SM, Simforoosh N, et al. The risk factors and laboratory diagnostics for post renal transplant tuberculosis: a case-control, country-wide study on definitive cases. Transpl Infect Dis. 2008;10:231-5.
6. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009;48:1657-65.
7. Canet E, Dantal J, Blancho G, et al. Tuberculosis following kidney transplantation: clinical features and outcome. A French multicentre experience in the last 20 years. Nephrol Dial Transplant. 2011; 26:3773-8.
8. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266-77.
9. Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12:2288-300.
10. Subramanian A, Dorman S. Practice ASTIDCo: Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S57-62.
11. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997; 63:1278-1286.
12. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect. 2003;9:518-25.
13. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. Eur Respir J. 2012; in press. This document provides an excellent consensus statement for tuberculosis in transplant recipients, including stem cell recipients.
14. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356:1099-104.
15. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33:956-73.
16. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-84.
17. Sester M, Sotgiu G, Lange C, et al. Interferon-g release assays for the diagnosis of active tuberculosis: a systematic review and metaanalysis. Eur Respir J. 2011;37:100-11.
18. Sester M, Sester U, Clauer P, et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int. 2004;65:1826-34.
19. Dinser R, Fousse M, Sester U, et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-Alpha blocking drugs using a novel flowcytometric interferon-gamma release assay. Rheumatology (Oxford). 2008;47:212-8.
20. Sester U, Junker H, Hodapp T, et al. Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant. 2006;21:3258-68.
21. Manuel O, Humar A, Preiksaitis J, et al. Comparison of Quantiferon-TB Gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant. 2007;7:2797-801.
22. Casas S, Munoz L, Moure R, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl. 2011;17:1205-11.
23. Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant. 2011;11:1927-35.
24. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49-58.
25. Diel R, Loddenkemper R, Niemann S, et al. Negative and positive predictive value of a whole-blood interferon-{gamma} release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011;183:88-95.
26. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-Analysis. Lancet Infect Dis. 2012;12:45-55. This meta-Analysis focuses on the positive predictive value of IGRAs for active tuberculosis in different patient cohorts.
27. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-15. The study demonstrated a sensitive and rapid detection of tuberculosis and rifampin resistance by molecular testing.
28. Miotto P, Bigoni S, Migliori GB, et al. Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J. 2012;39:1269-71.
29. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011; 184:132-40.
30. Sester U, Fousse M, Dirks J, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-Active states. PLoS One. 2011;6:e17813.
31. Streitz M, Tesfa L, Yildirim V, et al. Loss of receptor on tuberculinreactive T-cells marks active pulmonary tuberculosis. PLoS One. 2007;2:e735.
32. Harari A, Rozot V, Enders FB, et al. Dominant TNF-Alpha + Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med. 2011;17:372-6.
33. Theron G, Peter J, Lenders L, et al. Correlation of mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting. PLoS One. 2012;7:e37436.
34. Sester M, van Leth F, Girardi E, et al. Head-To-head analysis of IGRAs and skin-Testing in immunocompromised patients: Interim analysis of a multicenter TBNET study Eur Respir J. 2010; abstract
35. Field M, Clarke A, Kelleher M, et al. Anti-Tuberculosis prophylaxis following renal transplantation: acceptable variations? Transpl Infect Dis. 2012.
36. Page KR, Sifakis F. Montes de Oca R, et al.: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166: 1863-70.
37. Centers for Disease C, Prevention. Severe isoniazid-Associated liver injuries among persons being treated for latent tuberculosis infection -United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59:224-9.
38. Vikrant S, Agarwal SK, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7:99-108.
39. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation. 2010;90: 695-704.
40. Schluger LK, Sheiner PA, Jonas M, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med. 1996;63:364-9.
41. Higgins RM, Cahn AP, Porter D, et al. Mycobacterial infections after renal transplantation. Q J Med. 1991;78:145-53.
42. Agarwal SK, Gupta S, Dash SC, et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol. 2004;36:425-31.
43. Ram R, Swarnalatha G, Prasad N, et al. Tuberculosis in renal transplant recipients. Transpl Infect Dis. 2007;9:97-101.
44. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-Analysis. PLoS Med. 2009;6: e1000146.
45. Chang KC, Leung CC, Yew WW, et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:1153-8.
46. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48:1276-84.
47. Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15:1485-1489, i.
48. Narita M, Stambaugh JJ, Hollender ES, et al. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis. 2000;30:779-83.
49. Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A. 2011;108:19013-7.
50. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med. 2011;3:104ra102. This study elucidated a Vitamin D dependent mechanism of the adaptive immune system for defense of M. tuberculosis.
51. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242-50. This clinical trial assessed the effect of Vitamin D supplemtentation on sputum conversion of patients with active tuberculosis.
52. Sterling KA, Eftekhari P, Girndt M, et al.: The immunoregulatory function of vitamin D: implications in chronic kidney disease. Nat Rev Nephrol. 2012.